Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.orchidpharma.com | |
Market Cap | 5,301.16 Cr. | |
Enterprise Value(EV) | 5,397.33 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 23.22 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | 45.01 | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.54 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 224.38 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 4.66 | Calculated using Price: 1,045.20 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 5.07 Cr. | 50,719,105 Shares |
FaceValue | 10 | |
About Orchid Pharma Ltd. | ||
Orchid Chemicals & Pharmaceuticals (Orchid) is pharmaceutical company engaged in development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. The company was Incorporated in the year 1992 as a 100% export-oriented unit (EOU). |
1 Day |
|
+0.29% |
1 Week |
|
+4.01% |
1 Month |
|
-13.98% |
3 Month |
|
+48.18% |
6 Month |
|
+95.31% |
1 Year |
|
+170.14% |
2 Year |
|
+271.04% |
5 Year |
|
+19035.45% |
10 Year |
|
+2007.01% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | -55.58 | -147.51 | 0 | 0 | 0 | -423.17 | -13.43 | -8.75 | 8.27 | |
Return on Capital Employed (%) | 4.17 | -0.06 | -6.93 | -3.46 | 3.08 | -6.47 | -3.53 | -2.32 | 9.11 | |
Return on Assets (%) | -4.53 | -7.05 | -13.59 | -10.88 | 2.24 | -5.78 | -7.06 | -4.85 | 4.73 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 329 | 49 | -388 | -792 | -704 | 766 | 653 | 647 | 689 | 1,108 | |
Non Curr. Liab. | 2,609 | 2,475 | 2,205 | 1,905 | 1,436 | 519 | 442 | 222 | 165 | 145 | |
Curr. Liab. | 1,123 | 1,338 | 1,541 | 2,013 | 2,346 | 175 | 142 | 241 | 372 | 239 | |
Minority Int. | |||||||||||
Equity & Liab. | 4,061 | 3,862 | 3,358 | 3,125 | 3,077 | 1,460 | 1,237 | 1,111 | 1,225 | 1,492 | |
Non Curr. Assets | 2,783 | 2,611 | 2,479 | 2,446 | 2,310 | 891 | 687 | 713 | 724 | 995 | |
Curr. Assets | 1,278 | 1,251 | 879 | 679 | 767 | 569 | 550 | 384 | 501 | 497 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 4,061 | 3,862 | 3,358 | 3,125 | 3,077 | 1,460 | 1,237 | 1,111 | 1,225 | 1,492 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 1,747 | 873 | 797 | 683 | 600 | 484 | 450 | 560 | 666 | 812 | |
Other Income | 42 | 25 | 19 | 20 | 17 | 24 | 15 | 9 | 19 | 20 | |
Total Income | 1,789 | 898 | 816 | 703 | 617 | 508 | 465 | 569 | 685 | 832 | |
Total Expenditure | -1,429 | -703 | -709 | -659 | -612 | -515 | -399 | -505 | -582 | -692 | |
PBIDT | 360 | 196 | 106 | 45 | 5 | -7 | 66 | 64 | 104 | 140 | |
Interest | -537 | -294 | -331 | -310 | -7 | -6 | -52 | -33 | -33 | -20 | |
Depreciation | -325 | -145 | -141 | -133 | -130 | -118 | -109 | -87 | -55 | -32 | |
Taxation | 191 | 17 | 48 | 46 | |||||||
Exceptional Items | 113 | -53 | -173 | 201 | 39 | 39 | |||||
PAT | -197 | -279 | -490 | -353 | 69 | -131 | -95 | -57 | 55 | 127 | |
Minority Interest | 1 | ||||||||||
Share Associate | 0 | -4 | -2 | -2 | |||||||
Other Related Items | |||||||||||
Consolidated Net Profit | -197 | -279 | -490 | -353 | 70 | -131 | -117 | -2 | 46 | 118 | |
Adjusted EPS | -23 | -31 | -55 | -40 | 8 | -32 | -29 | 0 | 11 | 26 |
Particulars | 10 years | 2013-09 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 168 | -369 | 212 | 317 | 9 | 12 | 81 | 24 | 92 | 18 | |
Cash Fr. Inv. | -986 | 1,334 | -1 | -9 | -28 | 45 | 167 | 67 | 113 | -31 | |
Cash Fr. Finan. | 664 | -597 | -286 | -366 | 33 | 0 | -250 | -165 | -217 | 31 | |
Net Change | -153 | 367 | -76 | -58 | 15 | 57 | -2 | -74 | -11 | 18 | |
Cash & Cash Eqvt | 23 | 391 | 315 | 257 | 35 | 92 | 90 | 16 | 4 | 23 |
Wed, 27 Mar 2024
Intimation Regarding The Appeal Filed By The Company Against The Order Passed By 'ASSISTANT COMMISSIONER VALLUVARKOTTAM ASSESSMENT CIRCLE' W.R.T The Audit Conducted Under Section 65 For The Period 2017-18. In reference to the disclosure submitted by the Company dated January 31 2024 we would like to inform that the Company has filed an appeal before the GST Appeals Chennai-1 against the subjected order. |
Thu, 29 Feb 2024
Investor Roadshow Schedule Pursuant to Regulation 30 of Listing Regulation this is to inform that a Investor Roadshow is scheduled to be held on February 29 2024 in Mumbai. |
Fri, 23 Feb 2024
Announcement under Regulation 30 (LODR)-Press Release / Media Release Please find enclosed the Press Release being released titled "Orchid Pharmas Exblifep receives USFDA approval: A new milestone for Indias Pharmaceutical industry |
Thu, 28 Mar 2024 |
High Decrease in 1 Month |
High Increase in 3 Months |
High Increase in 6 Months |
High Increase in 1 Year |
High Increase in 2 Years |